Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P230013/S034

Edwards EVOQUE Tricuspid Valve Replacement System (9850EV)

Edwards Lifesciences, LLC · Decision date Oct 28, 2026

MEDTECHLEDGER EXPLANATIONP230013/S034

What did the FDA decide?

The FDA record for P230013/S034 describes a 30-day notice, dated 2026-10-28, with a reported purpose of implementing an alternative supplier of a chemical manufacturing aid. The listed supplement reason is a process change covering manufacturer, sterilizer, packager or supplier. The applicant is Edwards Lifesciences, LLC, and the product code is NPW, in the cardiovascular specialty.

The identifier ties the notice to the original PMA P230013, and the title names the Edwards EVOQUE tricuspid valve replacement system (9850EV). That relationship identifies the affected filing but does not make this supplement a new approval of the whole system, and a manufacturing notice is not an original PMA. The record does not name the chemical manufacturing aid, the prior or replacement supplier, affected lots or models, or any supporting data. The stated purpose is not independent proof of safety or clinical effectiveness, and the record supports no clinical or regulatory conclusion beyond this description.

FDA approval order statement

implementing an alternative supplier of a chemical manufacturing aid
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Oct 28, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P230013/S034
Regulatory pathway
PMA supplement
Product code
NPW
Decision code
OK30
Decision date
Oct 28, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Percutaneously Delivered Prostheses and Tricuspid Valves.

Product code
NPW
FDA device class
3

For the original device and its historical approval scope, see PMA P230013. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P230013 · Original PMA

    Edwards EVOQUE Tricuspid Valve Replacement System

  2. P230013/S027 · Related supplement

    EVOQUE Tricuspid Valve Replacement System

  3. P230013/S034 received

    Application receipt date recorded by FDA.

  4. P230013/S029 · Related supplement

    Edwards EVOQUE Tricuspid Valve Replacement System

  5. P230013/S033 · Related supplement

    EVOQUE Tricuspid Valve Replacement System

  6. P230013/S034 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P230013. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P230013

Product / regulatory recordCompanyPathwayDecision dateSource
Edwards Lifesciences, LLCPMA approvalFeb 1, 2024FDA
Edwards Lifesciences, LLCPMA supplementSep 16, 2026FDA
Edwards Lifesciences, LLCPMA supplementOct 19, 2026FDA
Edwards Lifesciences, LLCPMA supplementOct 21, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Edwards Lifesciences, LLC

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
One Edwards Way, Irvine, CA, 92614

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records